Students at The University of Alabama’s Culverhouse College of Business are moving beyond classroom theory and into the real work of biopharmaceutical asset scouting. Lōkahi Therapeutics™, a subsidiary of Glucotrack, Inc., has renewed its partnership with the college, opening another year where students work alongside industry professionals to identify and assess actual therapeutic assets through the ai² Pipeline division. The extension was announced in an official company press release on September 18, 2026, confirming that students will continue to take part in hands-on evaluation of biopharma assets.
The ai² model is specifically designed to identify and evaluate therapeutic assets that have been overlooked or are no longer being developed, using a capital-efficient approach to pipeline growth.
Students take on market analysis, intellectual property review, regulatory planning, and commercialization strategy. Their work feeds directly into Lōkahi’s asset-origination process and can influence partnership talks, licensing, or acquisitions. Brian Peters, Senior Vice President of the ai² Division at Lōkahi Therapeutics™, says, “Students are not working on simulations. They are evaluating real opportunities and learning how strategic decisions are made in biotechnology.”
Rob Morgan, Ph.D., who leads the BIZ Path, STEM Path, and CREATE Path to the MBA programs at The University of Alabama, sees the partnership as a rare chance for students to apply what they learn in class to real business problems, while gaining experience in the life sciences sector. The partnership is confirmed by the company, with academic confirmation expected if the university issues its own release.
Lōkahi Therapeutics is a wholly owned subsidiary of Glucotrack, Inc. (Nasdaq: GCTK), which is focused on developing novel diabetes technologies. The company’s headquarters are listed in both Rutherford, New Jersey, and La Jolla, California, as confirmed in the official press release.
Glucotrack, Inc., which operates Lōkahi, focuses on developing new diabetes technologies, including an investigational implantable continuous blood glucose monitoring system. The Culverhouse College of Business, accredited by AACSB since 1929, continues to give its students experience at the intersection of business and science, especially through its STEM Path to the MBA program.
By involving students in the real process of asset identification and evaluation, Lōkahi is testing its own sourcing and decision-making frameworks with new perspectives. This approach benefits both the company and the students, who gain firsthand insight into the realities of biopharma development. In a field where capital efficiency and clear strategy matter, Lōkahi’s model—based on live collaboration and careful analysis—offers a practical example of how to build value in biotech.
